Victoria Sharma
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Victoria Sharma.
PLOS ONE | 2012
Paolo Monini; Aurelio Cafaro; Indresh K. Srivastava; Sonia Moretti; Victoria Sharma; Claudia Andreini; Chiara Chiozzini; Flavia Ferrantelli; Maria Rosaria Pavone Cossut; Antonella Tripiciano; Filomena Nappi; Olimpia Longo; Stefania Bellino; Orietta Picconi; Emanuele Fanales-Belasio; Alessandra Borsetti; Elena Toschi; Ilaria Schiavoni; Ilaria Bacigalupo; Elaine Kan; Leonardo Sernicola; Maria Teresa Maggiorella; Katy Montin; Marco Porcu; Patrizia Leone; Pasqualina Leone; Barbara Collacchi; Clelia Palladino; Barbara Ridolfi; Mario Falchi
Use of Env in HIV vaccine development has been disappointing. Here we show that, in the presence of a biologically active Tat subunit vaccine, a trimeric Env protein prevents in monkeys virus spread from the portal of entry to regional lymph nodes. This appears to be due to specific interactions between Tat and Env spikes that form a novel virus entry complex favoring R5 or X4 virus entry and productive infection of dendritic cells (DCs) via an integrin-mediated pathway. These Tat effects do not require Tat-transactivation activity and are blocked by anti-integrin antibodies (Abs). Productive DC infection promoted by Tat is associated with a highly efficient virus transmission to T cells. In the Tat/Env complex the cysteine-rich region of Tat engages the Env V3 loop, whereas the Tat RGD sequence remains free and directs the virus to integrins present on DCs. V2 loop deletion, which unshields the CCR5 binding region of Env, increases Tat/Env complex stability. Of note, binding of Tat to Env abolishes neutralization of Env entry or infection of DCs by anti-HIV sera lacking anti-Tat Abs, which are seldom present in natural infection. This is reversed, and neutralization further enhanced, by HIV sera containing anti-Tat Abs such as those from asymptomatic or Tat-vaccinated patients, or by sera from the Tat/Env vaccinated monkeys. Thus, both anti-Tat and anti-Env Abs are required for efficient HIV neutralization. These data suggest that the Tat/Env interaction increases HIV acquisition and spreading, as a mechanism evolved by the virus to escape anti-Env neutralizing Abs. This may explain the low effectiveness of Env-based vaccines, which are also unlikely to elicit Abs against new Env epitopes exposed by the Tat/Env interaction. As Tat also binds Envs from different clades, new vaccine strategies should exploit the Tat/Env interaction for both preventative and therapeutic interventions.
Virology | 2006
Victoria Sharma; Elaine Kan; Yide Sun; Ying Lian; Jimna Cisto; Verna Frasca; Susan Hilt; Leonidas Stamatatos; John Donnelly; Jeffrey B. Ulmer; Susan W. Barnett; Indresh K. Srivastava
HIV envelope glycoprotein (Env) is the target for inducing neutralizing antibodies. Env is present on the virus surface as a trimer, and, upon binding to CD4, a cascade of events leads to structural rearrangement exposing the co-receptor binding site and entry into the CD4+ host target cells. We have designed monomeric and trimeric Env constructs with and without deletion of the variable loop 2 (ΔV2) from SF162, a subtype B primary isolate, and performed biophysical, biochemical and immunological studies to establish a potential structure–functional relationship. We expressed these Envs in CHO cells, purified the proteins to homogeneity and performed biophysical studies to define the binding properties to CD4, structural characteristics and exposure of epitopes recognized by b12 and CD4i mAb (17B) on both full-length and mutant HIV Env proteins. Parameters evaluated include oligomerization state, number and affinity of CD4 binding sites, enthalpy and entropy of the Env–CD4 interaction and affinity for b12 and 17b mAbs. We observed one CD4 binding site per monomer and three active CD4 binding sites per trimer. A40-fold difference in affinity of the gp120 monomer vs. the o-gp140 trimer towards CD4 was observed (Kd = 58 nM and 1.5 nM, respectively),whereas only a 2-fold difference was observed for the V2 deleted Envs (Kd of gp120ΔV2 = 19 nM, Kd of o-gp140DV2 = 9.3 nM). Monomers had 3-fold higher affinity to the mAb 17b and at least 3-fold weaker affinity to b12 compared to trimers, with gp120DV2 having the weakest affinity for b12 (Kd = 446 nM). Affinity of CD4 binding correlated with proportion of the antibodies induced against the conformational epitopes by the corresponding Envs, and changes in mAb binding correlated with the induction of antibodies directed against linear epitopes. Furthermore,biophysical analysis reveals that the V2 deletion has broad structural implications in the monomer not shared by the trimer, and these changes are reflected in the quality of the immune responses induced in rabbits. These data suggest that biophysical characteristics of HIV Env, such as affinity for CD4, and exposure of important neutralizing epitopes, such as those recognized by b12 mAb, may be important predictors of its in vivo efficacy and may serve as important surrogate markers for screening Env structures as potential vaccine candidates.
Virology | 2008
Indresh K. Srivastava; Elaine Kan; Yide Sun; Victoria Sharma; Jimna Cisto; Brian J. Burke; Ying Lian; Susan Hilt; Zohar Biron; Karin Hartog; Leonidas Stamatatos; R. Holland Cheng; Jeffrey B. Ulmer; Susan W. Barnett
Archive | 2005
Indresh K. Srivastava; Victoria Sharma; Susan W. Barnett; Jeffrey B. Ulmer
Archive | 2005
Vega Masignani; Maria Scarselli; Barbara Capecchi; Victoria Sharma; Susan W. Barnett; Indresh K. Srivastava; Rino Rappuoli
Archive | 2006
Susan W. Barnett; Rino Rappuoli; Victoria Sharma; Indresh K. Srivastava; Jan zur Megede
Archive | 2005
Vega Masignani; Maria Scarselli; Barbara Capecchi; Victoria Sharma; Susan W. Barnett; Indresh K. Srivastava; Rino Rappuoli
Archive | 2007
Victoria Sharma; Elaine Kan; Susan W. Barnett; Indresh K. Srivastava
Archive | 2012
Susan W. Barnett; Rino Rappuoli; Victoria Sharma; Indresh K. Srivastava; Jan zur Megede
Archive | 2012
Vega Masignani; Maria Scarselli; Barbara Capecchi; Victoria Sharma; Susan W. Barnett; Indresh K. Srivastava; Rino Rappuoli